# Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

> **NCT04363359** · PHASE2 · COMPLETED · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 1980 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** 0.5ml Quadrivalent influenza vaccine
- **BIOLOGICAL:** 0.25ml Quadrivalent influenza vaccine
- **BIOLOGICAL:** 0.25ml Trivalent influenza vaccine(B/V)
- **BIOLOGICAL:** 0.25ml Trivalent influenza vaccine(B/Y)

## Key facts

- **NCT ID:** NCT04363359
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-15
- **Primary completion:** 2021-09-14
- **Final completion:** 2021-09-14
- **Target enrollment:** 1980 (ACTUAL)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04363359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04363359, "Clinical Trial of Quadrivalent Influenza Virus Split Vaccine". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04363359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*